NAGE compared with MFIN: revenue, margins and what each company keeps, and the suppliers and customers both name

NAGENiagen Bioscience, Inc.

Mkt capRevenueRevenue

MFINMedallion Financial Corp

Mkt capRevenueRevenue

Compare

NAGENiagen Bioscience, Inc.

MFINMedallion Financial Corp

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

NAGE

2 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±12.6%▼−16.47%×1.31

Q2 FY26±27.5%▼−14.70%×0.53

May 7 '26±14.9%▼−15.69%×1.05

Q1 FY26±22.3%▲+3.24%×0.14

MFIN

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±15.5%▼−13.53%×0.87

Q2 FY26±15.0%▲+1.71%×0.11

= impliedNAGE realized, solidMFIN realized, hatchedOne scale, both sides: full bar = 28%× = |realized| ÷ impliedSource: market data

Q1 FY26

±18.1%

▼−1.08%

×0.06

Feb 19 '26±6.6%▼−1.98%×0.30

NAGENiagen Bioscience, Inc.

2.07▼−1.90%· post 2.07

Mkt cap$163.9MRevenue$27MQ3 FY26Revenue$129MFY25

MFINMedallion Financial Corp

10.05▲+1.31%· post 10.01

ClosedNov 6 '26

Mkt cap$224.1MRevenue$62MQ3 FY26Revenue$248MFY25

Compare

ClosedNov 6 '26

NAGENiagen Bioscience, Inc.

MFINMedallion Financial Corp

2.07▼−1.90%post 2.07

Price

10.05▲+1.31%post 10.01

$163.9M

Mkt cap

$224.1M

Q3 FY26$27M

Revenue

$62MQ3 FY26

FY25$129M

Revenue

$248MFY25

NAGE2.07▼−1.90%vsMFIN10.05▲+1.31%ClosedNov 6 '26